



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Xadago (safinamide)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Form with fields for Patient Name, Member/Subscriber Number, Date of Birth, Group Number, Address, City, State ZIP, Primary Phone, Prescriber Name, Supervising Physician, Fax, Office Contact, NPI, Address, City, State ZIP, Specialty/facility name, and State Lic ID.

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Is the prescriber a Neurologist?
Q2. Is the patient >=18 years of age?
Q3. Does the patient have a diagnosis of Parkinson's disease (PD)?
Q4. Please provide ICD code(s) for diagnosis.
Q5. Will the patient be using levodopa/carbidopa concomitantly?
Q6. Does the patient have "off" time greater than 1.5 hours per day, excluding morning akinesia?
Q7. Will the member have concomitant use of ANY of the following? Please select all that apply.



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Xadago (safinamide)

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:
	Supervising Physician:
linezolid) <input type="checkbox"/> Opioid drugs (e.g. tramadol, meperidine and related derivatives) <input type="checkbox"/> Selective norepinephrine reuptake inhibitors (SNRI) <input type="checkbox"/> Tri- or tetra-cyclic or triazolopyridine antidepressants <input type="checkbox"/> Cyclobenzaprine <input type="checkbox"/> Methylphenidate, amphetamine, and their derivatives <input type="checkbox"/> St. John's wort <input type="checkbox"/> Dextromethorphan <input type="checkbox"/> None of the above	
Q8. Does the patient have severe hepatic impairment (Child-Pugh C:10-15)? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. Please select all of the following that the patient has failure of or contraindication to. <input type="checkbox"/> Entacapone <input type="checkbox"/> Pramipexole <input type="checkbox"/> Rasagiline <input type="checkbox"/> Ropinirole <input type="checkbox"/> Tocapone <input type="checkbox"/> Selegiline <input type="checkbox"/> Other (please specify)	
Q10. Additional Comments	

Prescriber Signature

Date



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Xadago (safinamide)

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:

Prescriber Name:

Supervising Physician:

Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document